{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00019231", "CSN": null, "TRF": "ORD_1311284_01", "MRN": "48090820", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1051687", "clinicalId": "1053058", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1311284_01", "SampleName": "US1261351.01", "Version": "0", "Sample": {"FM_Id": "ORD_1311284_01", "SampleId": "US1261351.01", "BlockId": "S111-05399FSA", "TRFNumber": "ORD_1311284_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_03_01", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "20", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98635", "MRN": "48090820", "FullName": "\u9673\u8389\u9e97", "FirstName": "Li_Li", "LastName": "Chen", "SubmittedDiagnosis": "Metastatic pancreatic adenocarcinoma (From S111-89055)", "Gender": "Female", "DOB": "1964_10_12", "OrderingMD": "\u674e\u91cd\u8cd3", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Peritoneum", "CollDate": "2022_02_11", "ReceivedDate": "2022-03-15 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Pancreatic Cancer"}, "PertinentNegatives": {"PertinentNegative": {"Gene": "BRCA2"}}, "Summaries": {"alterationCount": "16", "clinicalTrialCount": "18", "resistiveCount": "0", "sensitizingCount": "4"}, "VariantProperties": {"VariantProperty": [{"geneName": "ERCC4", "isVUS": "true", "variantName": "C723*"}, {"geneName": "FGFR3", "isVUS": "true", "variantName": "G44S"}, {"geneName": "GNAS", "isVUS": "true", "variantName": "A436_P447del,R4H"}, {"geneName": "MAP3K13", "isVUS": "true", "variantName": "G107E"}, {"geneName": "NOTCH2", "isVUS": "true", "variantName": "R2298Q"}, {"geneName": "NOTCH3", "isVUS": "true", "variantName": "D2106Y"}, {"geneName": "POLE", "isVUS": "true", "variantName": "H2264Q"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "BRCA1", "Include": "true", "Alterations": {"Alteration": {"Name": "V11fs*12", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "V11fs*12"}}, "Interpretation": "The protein encoded by BRCA1 is involved in the maintenance of genomic stability, including DNA repair, cell cycle checkpoint, and chromosome segregation (O Donovan and Livingston, 2010; 20400477). Alterations such as seen here may disrupt BRCA1 function or expression (Nelson et al., 2010; 20681793, Silver and Livingston, 2012; 22843421, Ludwig et al., 2001; 11358863). In pancreatic carcinoma datasets, BRCA1 mutation and loss has been respectively reported in 1% and 0_1% of cases (cBio_Bailey et al., 2016; 26909576, cBio_Witkiewicz et al., 2015; 25855536). Reduced expression of BRCA1 at the mRNA and protein levels has been observed in pancreatic adenocarcinoma, with low or no expression of BRCA1 protein in 50% of cases (Beger et al., 2004; 15173085). Although most cases of pancreatic cancer are sporadic, germline mutations in BRCA1 and BRCA2 have been linked to an increased risk of pancreatic cancer, particularly in families of Ashkenazi Jewish descent (Lucas et al., 2013; 23658460, Friedenson, 2005; 16369438, Kim et al., 2012; 22406596, Naderi and Couch, 2002; 12622420, Stadler et al., 2012; 21598239). Reduced expression of BRCA1 at the mRNA and protein levels has been observed in pancreatic adenocarcinoma, with low or no expression of BRCA1 protein in 50% of cases; reduced or absent BRCA1 expression was found to be associated with poorer 1_year overall survival (Beger et al., 2004; 15173085). Alterations that inactivate BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors (Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Tutt et al., 2010; 20609467, Robson et al., 2017; 28578601, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788, Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934, Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755, Domchek et al., 2016; 26723501, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) or ATR inhibitors (Yap et al., 2020; 32988960, Thomas et al., 2018; 29252124, O Carrigan et al., 2016; ASCO Abstract 2504, Yap et al., 2016; AACR_NCI_EORTC Abstract 1LBA, Saito et al., 2018; 31299005). Clinical responses to PARP inhibitors have been reported for patients with either germline or somatic BRCA1/2 mutations (Mateo et al., 2015; 26510020, Swisher et al., 2016; 27908594, Ledermann et al., 2016; 27617661, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) and for patients with platinum_resistant or _refractory disease (Fong et al., 2010; 20406929, Kaufman et al., 2015; 25366685, Sandhu et al., 2013; 23810788, Domchek et al., 2016; 26723501). A randomized Phase 2 trial evaluating cisplatin and gemcitabine with or without veliparib in 50 patients with advanced pancreatic ductal adenocarcinomas (PDAC) harboring germline BRCA1/2 or PALB2 (gBRCA/PALB2+) mutations reported that the addition of the PARP inhibitor veliparib to chemotherapy did not significantly improve median PFS (10.1 vs. 9.7 months) or median OS (15.5 vs. 16.4 months) relative to chemotherapy alone (O\u2019Reilly et al., 2020; 31976786). In a Phase 1 trial of monotherapy treatment with the ATR inhibitor BAY1895344, 2 patients with deleterious BRCA1 alterations and platinum_refractory ovarian carcinoma experienced a PR or prolonged SD (Yap et al., 2020; 32988960). In other Phase 1 trials of combination approaches, a patient with BRCA1_mutated ovarian carcinoma experienced prolonged SD from the ATR inhibitor berzosertib combined with topotecan (Thomas et al., 2018; 29252124); another patient with platinum_ and PARP_inhibitory refractory ovarian cancer and an inactivating germline BRCA1 mutation experienced a PR from berzosertib plus carboplatin (O Carrigan et al., 2016; ASCO Abstract 2504); and a third patient with BRCA1_mutated triple_negative breast cancer (TNBC) experienced a PR to the ATR inhibitor ceralasertib combined with olaparib (Yap et al., 2016; AACR_NCI_EORTC Abstract 1LBA). Preclinical studies of BRCA1/2 inactivation in T_cell acute lymphoblastic leukemia (T_ALL) (Pouliot et al., 2019; 31721781), ovarian carcinoma (Kim et al., 2017; 27993965), and TNBC (Jin et al., 2018; 29605721) showing reduced cell viability and increased DNA damage during ATR treatment further support the sensitivity of BRCA1_deficient cells to ATR inhibitors. The WEE1 inhibitor adavosertib has been evaluated as a monotherapy and in combination with PARP_inhibitor, olaparib. In a Phase 2 study for patients with PARP_resistant ovarian cancer, the combination of olaparib and adavosertib elicited improved clinical benefit (ORR: 29%; DCR: 89%) compared to adavosertib alone (ORR: 23%; DCR: 63%); however, in the BRCA_mutated cohort, no significant difference in clinical benefit was observed between the combination (ORR: 19%) and monotherapy (ORR: 20%) treatments (Westin et al., 2021; ASCO Abstract 5505). In a Phase 1 monotherapy trial of adavosertib that included 9 patients with BRCA1/2_mutated solid tumors, 2 patients with BRCA1_mutated cancers (1 with ovarian serous carcinoma and 1 with oral squamous cell carcinoma) achieved PRs, and a third patient with ovarian serous carcinoma harboring mutations in BRCA1 and TP53 experienced 14% tumor shrinkage prior to disease progression (Do et al., 2015; 25964244). Inactivation of BRCA1 may also predict sensitivity to the DNA_damaging agents trabectedin and lurbinectedin (Cruz et al., 2018; 30240327, Awada et al., 2018; ASCO Abstract 1072, Poveda et al., 2017; 28368437, Garcia et al., 2013; 23364677, Sch\u00f6ffski et al., 2011; 21376569, Aracil et al., 2014; Abstract 35, Italiano et al., 2011; 21287534, Laroche_Clary et al., 2015; 25602962, Ghouadni et al., 2017; 28467918, Tedesco et al., 2011; ASCO Abstract 1125, Monk et al., 2015; 25722380, Monk et al., 2020; 31924332, Yasui et al., 2016; 27077926). Patients with pancreatic cancer and BRCA1/2 or PALB2 mutations may benefit from FOLFIRINOX, or the combination of cisplatin and gemcitabine (NCCN Pancreatic Adenocarcinoma Guidelines v2.2021)(Conroy et al., 2011; 21561347, Fogelman et al., 2015; 26126726,O\u2019Reilly et al., 2020; 31976786, Wattenberg et al., 2020; 31787751, Golan et al., 2014; 25072261). Inactivating germline mutations in BRCA1 or BRCA2 are associated with autosomal dominant hereditary breast and ovarian cancer (Miki et al., 1994; 7545954, Wooster et al., 1995; 8524414), and the lifetime risk of breast and ovarian cancer in BRCA1/2 mutation carriers has been estimated to be as high as 87% and 44%, respectively (Ford et al., 1994; 7907678). Elevated risk for other cancer types, including gastric, pancreatic, prostate, and colorectal, has also been identified, with an increase in risk ranging from 20 to 60% (Friedenson, 2005; 16369438). The estimated prevalence of deleterious germline BRCA1/2 mutations in the general population is between 1:400 and 1:800, with an approximately 10_fold higher prevalence in the Ashkenazi Jewish population (Ford et al., 1994; 7907678, Whittemore et al., 1997; 9042908, Claus et al., 1996; 8635102, Struewing et al., 1997; 9145676, Oddoux et al., 1996; 8841192, King et al., 2003; 14576434, Hall et al., 2009; 19241424). In the appropriate clinical context, germline testing of BRCA1 is recommended.", "Include": "true", "ClinicalTrialNote": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Rucaparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration_resistant prostate cancer (mCRPC) or epithelial ovarian, Fallopian tube, or primary peritoneal cancer and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence in ovarian cancer (Shapira_Frommer et al., 2015; ASCO Abstract 5513)(Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934), as well as clinical data in other cancer types (Kristeleit et al., 2014; ASCO Abstract 2573, Domcheck et al., 2016; ASCO Abstract 4110)(Drew et al., 2016; 27002934), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib. </p> <p><b>Supporting Data:</b> In the RUCAPANC Phase 2 study, rucaparib elicited an ORR of 15.8% and a DCR of 31.6% in BRCA1/2_mutated advanced or metastatic pancreatic cancer, with 1 CR and 2 PRs confirmed and 1 additional unconfirmed CR out of 19 treated patients (Shroff et al., 2018; 30051098). In a Phase 2 study, rucaparib monotherapy elicited 1 CR, 6 PRs, an ORR of 36.8%, and a DCR (CR+PR+SD) of 89.5% in a cohort of 19 patients with advanced pancreatic carcinoma harboring germline or somatic mutations in BRCA or PALB2 (Binder et al., 2019; AACR Abstract CT234). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Talazoparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor talazoparib is FDA approved to treat HER2_negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical data in breast cancer (Turner et al., 2017; ASCO Abstract 1007)(Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753) and additional clinical evidence in ovarian, pancreatic, and prostate cancer (Meehan et al., 2017; AACR Abstract 4687)(de Bono et al., 2017; 28242752, Lu et al., 2018; 30099369, De Bono et al., 2020; ASCO Abstract 5566), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib. </p> <p><b>Supporting Data:</b> A Phase 1 study of talazoparib reported 2 PRs for patients with pancreatic cancer and a BRCA2 or PALB2 mutation (deBono et al., 2017; 28242752). Talazoparib has been studied primarily in the context of BRCA_mutated, HER2_negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study (Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753). In a Phase 2 study of talazoparib for BRCA1/2_wildtype patients with homologous recombination pathway alterations, the best outcome in non_breast tumors was SD \u2265 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration (Gruber et al., 2019; ASCO Abstract 3006). Clinical activity of single_agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA_mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2_mutated pancreatic and bladder cancers; ATM_mutated cholangiocarcinoma; and small cell lung cancer (deBono et al., 2017; 28242752, Lu et al., 2018; 30099369)(Piha_Paul et al., 2017; EORTC_NCI_AACR Abstract A096, Meehan et al., 2017; AACR Abstract 4687). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Niraparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)_positive status. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in ovarian and breast cancers (Konstantinopolous et al., 2018; ASCO Abstract 106, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of niraparib for the treatment of pancreatic cancer are limited (PubMed, Jan 2022)(Chi et al., 2021; 34025781). Niraparib has been primarily evaluated in the context of ovarian cancer. In a Phase 3 study of patients with platinum_sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS, as compared to placebo, in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months) as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination_deficient tumors (12.9 vs. 3.8 months)(Mirza et al., 2016; 27717299). In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration_resistant prostate cancer and 100% (2/2) of patients with non_small cell lung cancer achieved SD (Sandhu et al., 2013; 23810788). A Phase 1 study of the combination of niraparib and bevacizumab in patients with platinum_sensitive, high_grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)(Mirza et al., 2016; ASCO Abstract 5555). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Olaparib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA_mutated pancreatic adenocarcinoma or HER2_negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of extensive clinical evidence in ovarian cancer (Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755) as well as strong clinical evidence in multiple other cancer types (Fong et al., 2009; 19553641, Tutt et al., 2010; 20609467, Gelmon et al., 2011; 21862407, Del Conte et al., 2014; 25025963, Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Golan et al., 2019; 31157963), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib. </p> <p><b>Supporting Data:</b> In a Phase 2 study of olaparib plus pembrolizumab for advanced solid tumors, patients with BRCA1 or BRCA2 mutations achieved an ORR of 29% (6/21), whereas patients with mutations in other homologous recombination repair genes achieved an ORR of 6.3% (2/32) (Maio et al., 2021; AACR Abstract CT178). The Phase 3 randomized, placebo_controlled POLO trial investigating maintenance olaparib for patients with platinum_sensitive, germline BRCA1/2_mutated metastatic pancreatic adenocarcinoma reported a significantly longer median PFS compared with placebo (7.4 vs. 3.8 months, HR=0.53) (Golan et al., 2019; 31157963). At 3_year follow_up, an OS of 34% was reported for patients treated with olaparib compared with 18% for patients receiving placebo; however, olaparib maintenance therapy did not impact median OS (19.0 vs. 19.2 months, HR=0.83) relative to placebo (Golan et al., 2021; ASCO Abstract 378). A Phase 2 trial of olaparib monotherapy for patients with germline BRCA1/2_mutated recurrent pancreatic cancer reported a response rate of 22% (Kaufman et al., 2015; 25366685). Parallel Phase 2 trials reported 2 PRs for patients with platinum_sensitive, DNA damage repair (DDR) deficient, germline BRCA mutation_negative pancreatic ductal adenocarcinoma; no responses were observed in platinum_refractory cases (Golan et al., 2018; ASCO Abstract 297). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04300114", "Include": "true"}, {"nctId": "NCT04768296", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04228601", "Include": "true"}, {"nctId": "NCT04425876", "Include": "true"}, {"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "G12D", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "G12D"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870, Loree et al., 2021; 34117033). KRAS mutations have been observed in 91_95% of pancreatic ductal adenocarcinoma cases (cBio_Biankin et al., 2012; 23103869, cBio_Witkiewicz et al., 2015; 25855536), with the majority of mutations found at codon 12 (Feldmann et al., 2007; 17520196, Rachakonda et al., 2013; 23565280, Hruban et al., 1993; 8342602, Maitra et al., 2006; 16549325). KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma (Rachakonda et al., 2013; 23565280). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). Initial Phase 1 monotherapy trials of MEK inhibitors in patients with pancreatic cancer showed promise, with DCR (PR and/or SD) up to 37% (Bodoky et al., 2012; 21594619), response rates up to 25% (Rosen et al., 2008; ASCO Abstract 14585, Rinehart et al., 2004; 15483017, LoRusso et al., 2005; 16009947, Bodoky et al., 2012; 21594619, Infante et al., 2012; 22805291, Weekes et al., 2013; 23434733), and prolonged PRs in certain patients (Rinehart et al., 2004; 15483017, Infante et al., 2012; 22805291, Garrido_Laguna et al., 2015; 25897431). However, subsequent clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status (Van Laethem et al., 2017; 27975152, Infante et al., 2013; 23583440, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), with refametinib and gemcitabine even showing a trend towards worse response and survival in patients with KRAS_mutant pancreatic tumors than in those with KRAS wild_type tumors (OS 6.6 months vs 18.2 months) (Van Laethem et al., 2017; 27975152). Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors (Ko et al., 2016; 26251290) or PI3K_AKT pathway inhibitors (LoRusso et al., 2012; ASCO Abstract 2566, Juric et al., 2014; ASCO Abstract 9051, Chung et al., 2017; 27978579, Bedard et al., 2015; 25500057), reported no PRs and frequent adverse events in patients with KRAS_mutant pancreatic cancer. Emerging preclinical studies suggest MEK inhibition downstream of KRAS_mutant pancreatic tumors leads to increased autophagy (Kinsey et al., 2019; 30833748, Bryant et al., 2019; 30833752). Combination MEK/autophagy inhibitors may therefore be more beneficial. A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine exhibited a PR (Kinsey et al., 2019; 30833748). A Phase 2 trial of paclitaxel/carboplatin with or without Reolysin in patients with metastatic pancreatic adenocarcinoma reported no improvement in PFS with addition of Reolysin, regardless of KRAS mutational status (Noonan et al., 2016; 27039845); however a Phase 2 study of Reolysin and gemcitabine in patents with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs in 34 patients with a favorable median OS of 10.2 months (Mahalingam et al., 2018; 29799479). In a Phase 1 study evaluating the MEK_pan_RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non_small cell lung cancer (NCSLC), 1 with low_grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma (Guo et al., 2020; 33128873). Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS_mutated low_grade serous ovarian cancer and 12% (2/17) for patients with KRAS_mutated non_small cell lung cancer (NSCLC) in a Phase 1 study (Krebs et al., 2021; AACR Abstract CT019, Shinde et al., 2020; AACR Abstract CT143). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors (Hillig et al., 2019; 30683722, Hofmann et al., 2021; 32816843, Gerlach et al., 2020; AACR Abstract 1091). Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations (Hofmann et al., 2021; AACR Abstract CT210, Gort et al., 2020; ASCO Abstract TPS3651).", "Include": "true", "ClinicalTrialNote": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03825289", "Include": "true"}, {"nctId": "NCT04132505", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": {"Name": "duplication exon 4", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "duplication exon 4"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). PTEN mutations are rare in pancreatic adenocarcinomas and have been observed in fewer than 1% of cases (cBio_Biankin et al., 2012; 23103869, cBio_Witkiewicz et al., 2015; 25855536); PTEN homozygous deletion was observed in 1.8% of pancreatic ductal adenocarcinomas (cBio_Witkiewicz et al., 2015; 25855536). Reduced or loss of PTEN protein expression has been reported in approximately 26% (34/133) to 70% (38/54) of pancreatic ductal adenocarcinoma samples (Foo et al., 2012; 23260327, Ying et al., 2011; 21984975). Loss of PTEN protein expression has been associated with local recurrence or distant metastasis as well as poor prognosis in pancreatic ductal adenocarcinoma patients (Foo et al., 2012; 23260327). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Across various tissues, most clinical studies have not observed an association between PTEN deficiency and response to inhibitors of the PI3K_AKT_mTOR pathway. However, limited studies in prostate cancer (Templeton et al., 2013; 23582881, Sweeney et al., 2021; 34246347, de Bono et al., 2019; 30037818, Saura et al., 2017; 27872130), renal cell carcinoma (Voss et al., 2019; 30327302), breast cancer (Andre et al., 2016; 27091708, Dent et al., 2018; ASCO Abstract 1008, Schmid et al., 2020; 31841354), and colorectal cancer (Gilcrease et al., 2019; 30302599) have reported an association between PTEN deficiency and response to inhibitors targeting the PI3K_AKT_mTOR pathway. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04425876", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04001569", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04632992", "Include": "true"}, {"nctId": "NCT03907969", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ATR", "Include": "true", "Alterations": {"Alteration": {"Name": "duplication exon 36", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "duplication exon 36"}}, "Interpretation": "ATR encodes the protein ataxia telangiectasia and RAD3 related, which phosphorylates the tumor suppressor BRCA1, and several cell cycle checkpoint proteins including CHK1; it plays a key role in maintaining genome integrity via regulation of DNA repair and replication (Ha et al., 2011; 21566061, Liang et al., 2009; 19034564). Alterations such as seen here may disrupt ATR function or expression (Mordes et al., 2008; 18519640). In the Pancreatic Adenocarcinoma TCGA dataset, ATR mutations have been reported in up to 2.2% of cases (cBioPortal, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). ATR mutations have been reported in 3% of pancreas carcinoma samples analyzed (COSMIC, Mar 2021)(Tate et al., 2019; 30371878). ATR inactivation, either by mutation or decreased expression, is associated with increased microsatellite instability (MSI) and chromosome instability (CIN) in a variety of tumor types, including colorectal and endometrial cancers (Vassileva et al., 2002; 12124347, Miquel et al., 2007; 17384679, Jardim et al., 2009; 19570909). In one study, expression of phosphorylated ATR positively correlated with histological grade in pancreatic cancer samples but was not predictive of overall survival (Zhou et al., 2020; 32456796). A Phase 2 study reported talazoparib led to a SD lasting over 6 months for a patient with ATR_mutated breast cancer (Gruber et al., 2019; ASCO Abstract 3006). Based on preclinical evidence, ATR_deficient tumors may be sensitive to PARP inhibitors (Peasland et al., 2011; 21730979, McCabe et al., 2006; 16912188). ATR inactivation has been associated with increased sensitivity to 5_fluorouracil and cisplatin, but not to oxaliplatin, in cancer cell lines (Jardim et al., 2009; 19570909, Lewis et al., 2009; 1937255, Sangster_Guity et al., 2011; 21258400); however, this has not been demonstrated clinically.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "DNMT3A", "Include": "true", "Alterations": {"Alteration": {"Name": "P904L", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "P904L"}}, "Interpretation": "The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation (Trowbridge and Orkin, 2012; 22200773, Ch\u00e9din, 2011; 21507354). The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor (Yang et al., 2011; 21887466, Vallb\u00f6hmer et al., 2006; 16870044, Daskalos et al., 2011; 21351083, Fabbri et al., 2007; 17890317, Gao et al., 2011; 22011581, Kim et al., 2013; 23031157). Alterations such as seen here may disrupt DNMT3A function or expression (Chen et al., 2005; 15861382, Guo et al., 2015; 25383530, Sandoval et al., 2019; 30705090, Zhang et al., 2018; 29414941). DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2022). There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI is rare in pancreatic carcinoma, reported in less than 1% of samples (n=>1,000)(Hu et al., 2018; 29367431, Campbell et al., 2017; 29056344, Pihlak et al., 2018; 29329208, Salem et al., 2018; 29523759, Lahgi et al., 2012; 23029359). The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2021). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "PBRM1", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 3049_1G>A", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 3049_1G>A"}}, "Interpretation": "PBRM1 (Polybromo_1), also known as BAF180, encodes a subunit of ATP_dependent chromatin_remodeling complexes and a required cofactor for ligand_dependent transactivation by nuclear hormone receptors (Lemon et al., 2001; 11780067). Mutation, loss, or inactivation of PBRM1 has been reported in several cancers, suggesting PBRM1 is a tumor suppressor (Varela et al., 2011; 21248752, Jiao et al., 2013; 24185509, Xia et al., 2008; 18339845). Alterations such as seen here may disrupt PBRM1 function or expression (Hopson and Thompson, 2017; 28921948, Porter et al., 2017; 28053089, Niimi et al., 2015; 26117423, Brownlee et al., 2014; 24613357, Kakarougkas et al., 2014; 25066234, Gao et al., 2017; 28082722). Somatic mutations in PBRM1 are prevalent in clear cell renal cell carcinomas (ccRCC) (41%) (Varela et al., 2011; 21248752), intrahepatic cholangiocarcinomas (9_13%) (Fujimoto et al., 2015; 25636086, Jiao et al., 2013; 24185509, Churi et al., 2014; 25536104, Simbolo et al., 2014; 24867389), and bladder urothelial carcinomas (6_14%) (cBio_Cancer Genome Atlas Research Network, 2014; 24476821, cBio_Robertson et al., 2017; 28988769, cBio_Pietzak et al., 2017; 28583311). PBRM1 mutations are detected in other tumor types, including in 37% (11/30) of papillary meningiomas and 4% (2/54) of thymic carcinomas (Williams et al., 2020; 32405805, Petrini et al., 2014; 24974848) and in tumors of the skin (7.3%), stomach (5.8%), large intestine (4.8%), lung (2.6%), and soft tissue (2.4%) (COSMIC, Jan 2022)(Tate et al., 2019; 30371878). Preclinical studies have shown that loss of PBRM1 increases the proliferation of ccRCC cell lines (Varela et al., 2011; 21248752). PBRM1 protein loss or mutation is correlated with late tumor stage, low differentiation grade, and/or poor patient prognosis in ccRCC (da Costa et al., 2014; 24053427, Paw\u0142owski et al., 2013; 22949125, Hakimi et al., 2013; 23036577), extrahepatic cholangiocarcinoma (Churi et al., 2014; 25536104), and pancreatic cancer (Numata et al., 2013; 23229642). However, one ccRCC study reported no correlation between PBRM1 mutation and cancer_specific survival (Hakimi et al., 2013; 23620406). In ccRCC, PBRM1 alterations are generally observed to be mutually exclusive with BAP1 alterations (Varela et al., 2011; 21248752, Pena_Llopis et al., 2012; 22683710); a retrospective analysis of 145 primary ccRCCs found a decreased median overall survival for patients with mutations in both BAP1 and PBRM1 compared with patients having either mutated gene alone (Kapur et al., 2013; 23333114). A trend toward worse survival was also seen in patients with intrahepatic cholangiocarcinoma harboring mutations in chromatin modifiers (including BAP1, ARID1A, or PBRM1) (Jiao et al., 2013; 24185509). On the basis of significant clinical data from prospective studies, PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, for patients with clear cell renal cell carcinoma and prior anti_angiogenic therapy (Braun et al., 2019; 31486842, Braun et al., 2020; 32472114, Vano et al., 2020; ASCO GU Abstract 618, Miao et al., 2018; 29301960). However, multiple retrospective analyses report that PBRM1 mutation status is not associated with clinical benefit from various immune checkpoint inhibitors in other solid tumor types, including non_small cell lung cancer, urothelial carcinoma, melanoma, or esophagogastric cancer, suggesting that the impact of PBRM1 loss of function may depend on tumor type (Abou Alaiwi et al., 2020; 32321774, Hakimi et al., 2020; 32820162, Miao et al., 2018; 30150660, Yang et al., 2021; 33850862).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). Elevated TMB has been reported to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in multiple solid tumor types (Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915). However, the TMB level in this sample could not be determined with confidence. Pancreatic carcinomas, including ductal and acinar subtypes, have been reported to harbor a median TMB of 2_3 mutations per megabase (muts/Mb), and 0_2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421); TMB has not been assessed in pancreatic mucinous neoplasms (PubMed, Oct 2021). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69_314 months) compared to those with lower TMB (average of 5.7 mutations; 10_42 months) (Hu et al., 2017; ASCO Abstract e15791). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors. As the TMB status of this tumor cannot be determined with confidence, the benefit of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum_Based Chemotherapy", "StudyPhase": "PHASE 3", "Target": "PARP", "Locations": "Hangzhou (China), Shanghai (China), Nanjing (China), Hefei (China), Guangzhou (China), Wuhan (China), Zhengzhou (China), Jinan (China), Chongqing (China), Tianjin (China)", "NCTID": "NCT04300114", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "Berzosertib + Topotecan in Relapsed Platinum_Resistant Small_Cell Lung Cancer (DDRiver SCLC 250)", "StudyPhase": "PHASE 2", "Target": "TOP1, ATR", "Locations": "Hangzhou (China), Nanjing (China), Wuhan (China), Xi an (China), Osaka (Japan), Beijing (China), Hirakata_shi (Japan), Takatsuki_shi (Japan), Chengdu (China), Chuo_ku (Japan)", "NCTID": "NCT04768296", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer", "StudyPhase": "PHASE 1/2", "Target": "PARP", "Locations": "Hangzhou (China), Shanghai (China)", "NCTID": "NCT04228601", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Shanghai (China)", "NCTID": "NCT04425876", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Darlinghurst (Australia), Moscow (Russian Federation), Krasnogorsk (Russian Federation)", "NCTID": "NCT03742895", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)", "NCTID": "NCT02264678", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA1", "Alteration": "V11fs*12", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Utah", "NCTID": "NCT03825289", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Texas", "NCTID": "NCT04132505", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Shanghai (China)", "NCTID": "NCT04425876", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "AZD8186 and Paclitaxel in Advanced Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_beta", "Locations": "Seongnam_si (Korea, Republic of)", "NCTID": "NCT04001569", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, PD_L1, ERBB2, PI3K_alpha, RET, AKTs", "Locations": "Alaska, Washington, Oregon, California, Idaho", "NCTID": "NCT04632992", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti_cancer Agents in Patients With Advanced Cancers", "StudyPhase": "PHASE 1/2", "Target": "PARP, DNA_PK", "Locations": "Newcastle upon Tyne (United Kingdom), London (United Kingdom), Connecticut, Texas", "NCTID": "NCT03907969", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "duplication exon 4", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Washington, Oregon, Idaho, Montana", "NCTID": "NCT03994796", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "20400477", "FullCitation": "O Donovan PJ, et al. Carcinogenesis (2010) pmid: 20400477", "Include": "true"}, {"number": "1", "ReferenceId": "20681793", "FullCitation": "Nelson AC, et al. Radiat. Res. (2010) pmid: 20681793", "Include": "true"}, {"number": "2", "ReferenceId": "22843421", "FullCitation": "Silver DP, et al. Cancer Discov (2012) pmid: 22843421", "Include": "true"}, {"number": "3", "ReferenceId": "11358863", "FullCitation": "Ludwig T, et al. Genes Dev. (2001) pmid: 11358863", "Include": "true"}, {"number": "4", "ReferenceId": "26909576", "FullCitation": "Bailey P, et al. Nature (2016) pmid: 26909576", "Include": "true"}, {"number": "5", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "6", "ReferenceId": "15173085", "FullCitation": "Beger C, et al. Clin. Cancer Res. (2004) pmid: 15173085", "Include": "true"}, {"number": "7", "ReferenceId": "23658460", "FullCitation": "Lucas AL, et al. Clin. Cancer Res. (2013) pmid: 23658460", "Include": "true"}, {"number": "8", "ReferenceId": "16369438", "FullCitation": "MedGenMed (2005) pmid: 16369438", "Include": "true"}, {"number": "9", "ReferenceId": "22406596", "FullCitation": "Kim R, et al. JOP (2012) pmid: 22406596", "Include": "true"}, {"number": "10", "ReferenceId": "12622420", "FullCitation": "Naderi A, et al. Int J Gastrointest Cancer (2002) pmid: 12622420", "Include": "true"}, {"number": "11", "ReferenceId": "21598239", "FullCitation": "Stadler ZK, et al. Cancer (2012) pmid: 21598239", "Include": "true"}, {"number": "12", "ReferenceId": "25366685", "FullCitation": "Kaufman B, et al. J. Clin. Oncol. (2015) pmid: 25366685", "Include": "true"}, {"number": "13", "ReferenceId": "26510020", "FullCitation": "Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020", "Include": "true"}, {"number": "14", "ReferenceId": "20609467", "FullCitation": "Tutt A, et al. Lancet (2010) pmid: 20609467", "Include": "true"}, {"number": "15", "ReferenceId": "28578601", "FullCitation": "Robson M, et al. N. Engl. J. Med. (2017) pmid: 28578601", "Include": "true"}, {"number": "16", "ReferenceId": "27717299", "FullCitation": "Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299", "Include": "true"}, {"number": "17", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "18", "ReferenceId": "27908594", "FullCitation": "Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594", "Include": "true"}, {"number": "19", "ReferenceId": "27002934", "FullCitation": "Drew Y, et al. Br. J. Cancer (2016) pmid: 27002934", "Include": "true"}, {"number": "20", "ReferenceId": "28754483", "FullCitation": "Pujade_Lauraine E, et al. Lancet Oncol. (2017) pmid: 28754483", "Include": "true"}, {"number": "21", "ReferenceId": "27617661", "FullCitation": "Ledermann JA, et al. Lancet Oncol. (2016) pmid: 27617661", "Include": "true"}, {"number": "22", "ReferenceId": "19553641", "FullCitation": "Fong PC, et al. N. Engl. J. Med. (2009) pmid: 19553641", "Include": "true"}, {"number": "23", "ReferenceId": "20609468", "FullCitation": "Audeh MW, et al. Lancet (2010) pmid: 20609468", "Include": "true"}, {"number": "24", "ReferenceId": "20406929", "FullCitation": "Fong PC, et al. J. Clin. Oncol. (2010) pmid: 20406929", "Include": "true"}, {"number": "25", "ReferenceId": "21862407", "FullCitation": "Gelmon KA, et al. Lancet Oncol. (2011) pmid: 21862407", "Include": "true"}, {"number": "26", "ReferenceId": "22203755", "FullCitation": "Kaye SB, et al. J. Clin. Oncol. (2012) pmid: 22203755", "Include": "true"}, {"number": "27", "ReferenceId": "26723501", "FullCitation": "Domchek SM, et al. Gynecol. Oncol. (2016) pmid: 26723501", "Include": "true"}, {"number": "28", "ReferenceId": "30345884", "FullCitation": "Moore K, et al. N. Engl. J. Med. (2018) pmid: 30345884", "Include": "true"}, {"number": "29", "ReferenceId": "31157963", "FullCitation": "Golan T, et al. N. Engl. J. Med. (2019) pmid: 31157963", "Include": "true"}, {"number": "30", "ReferenceId": "32988960", "FullCitation": "Yap TA, et al. Cancer Discov (2021) pmid: 32988960", "Include": "true"}, {"number": "31", "ReferenceId": "29252124", "FullCitation": "Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124", "Include": "true"}, {"number": "32", "ReferenceId": "31299005", "FullCitation": "Saito YD, et al. Cancer Treat Res Commun (2018) pmid: 31299005", "Include": "true"}, {"number": "33", "ReferenceId": "31976786", "FullCitation": "O Reilly EM, et al. J. Clin. Oncol. (2020) pmid: 31976786", "Include": "true"}, {"number": "34", "ReferenceId": "31721781", "FullCitation": "Pouliot GP, et al. PLoS ONE (2019) pmid: 31721781", "Include": "true"}, {"number": "35", "ReferenceId": "27993965", "FullCitation": "Kim H, et al. Clin. Cancer Res. (2017) pmid: 27993965", "Include": "true"}, {"number": "36", "ReferenceId": "29605721", "FullCitation": "Jin J, et al. Neoplasia (2018) pmid: 29605721", "Include": "true"}, {"number": "37", "ReferenceId": "25964244", "FullCitation": "Do K, et al. J. Clin. Oncol. (2015) pmid: 25964244", "Include": "true"}, {"number": "38", "ReferenceId": "30240327", "FullCitation": "Cruz C, et al. J. Clin. Oncol. (2018) pmid: 30240327", "Include": "true"}, {"number": "39", "ReferenceId": "28368437", "FullCitation": "Poveda A, et al. Ann. Oncol. (2017) pmid: 28368437", "Include": "true"}, {"number": "40", "ReferenceId": "23364677", "FullCitation": "Garc\u00eda MJ, et al. Mol. Cancer Ther. (2013) pmid: 23364677", "Include": "true"}, {"number": "41", "ReferenceId": "21376569", "FullCitation": "Sch\u00f6ffski P, et al. Eur. J. Cancer (2011) pmid: 21376569", "Include": "true"}, {"number": "42", "ReferenceId": "21287534", "FullCitation": "Italiano A, et al. Cancer (2011) pmid: 21287534", "Include": "true"}, {"number": "43", "ReferenceId": "25602962", "FullCitation": "Laroche_Clary A, et al. Br. J. Cancer (2015) pmid: 25602962", "Include": "true"}, {"number": "44", "ReferenceId": "28467918", "FullCitation": "Ghouadni A, et al. Breast (2017) pmid: 28467918", "Include": "true"}, {"number": "45", "ReferenceId": "25722380", "FullCitation": "Monk BJ, et al. Ann. Oncol. (2015) pmid: 25722380", "Include": "true"}, {"number": "46", "ReferenceId": "31924332", "FullCitation": "Monk BJ, et al. Gynecol. Oncol. (2020) pmid: 31924332", "Include": "true"}, {"number": "47", "ReferenceId": "27077926", "FullCitation": "Yasui H, et al. J Chemother (2016) pmid: 27077926", "Include": "true"}, {"number": "48", "ReferenceId": "21561347", "FullCitation": "Conroy T, et al. N Engl J Med (2011) pmid: 21561347", "Include": "true"}, {"number": "49", "ReferenceId": "26126726", "FullCitation": "Fogelman D, et al. Cancer Chemother Pharmacol (2015) pmid: 26126726", "Include": "true"}, {"number": "50", "ReferenceId": "31787751", "FullCitation": "Wattenberg MM, et al. Br J Cancer (2020) pmid: 31787751", "Include": "true"}, {"number": "51", "ReferenceId": "25072261", "FullCitation": "Golan T, et al. Br J Cancer (2014) pmid: 25072261", "Include": "true"}, {"number": "52", "ReferenceId": "7545954", "FullCitation": "Miki Y, et al. Science (1994) pmid: 7545954", "Include": "true"}, {"number": "53", "ReferenceId": "8524414", "FullCitation": "Wooster R, et al. Nature () pmid: 8524414", "Include": "true"}, {"number": "54", "ReferenceId": "7907678", "FullCitation": "Ford D, et al. Lancet (1994) pmid: 7907678", "Include": "true"}, {"number": "55", "ReferenceId": "9042908", "FullCitation": "Whittemore AS, et al. Am. J. Hum. Genet. (1997) pmid: 9042908", "Include": "true"}, {"number": "56", "ReferenceId": "8635102", "FullCitation": "Claus EB, et al. Cancer (1996) pmid: 8635102", "Include": "true"}, {"number": "57", "ReferenceId": "9145676", "FullCitation": "Struewing JP, et al. N. Engl. J. Med. (1997) pmid: 9145676", "Include": "true"}, {"number": "58", "ReferenceId": "8841192", "FullCitation": "Oddoux C, et al. Nat. Genet. (1996) pmid: 8841192", "Include": "true"}, {"number": "59", "ReferenceId": "14576434", "FullCitation": "King MC, et al. Science (2003) pmid: 14576434", "Include": "true"}, {"number": "60", "ReferenceId": "19241424", "FullCitation": "Hall MJ, et al. Cancer (2009) pmid: 19241424", "Include": "true"}, {"number": "61", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "62", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "63", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "64", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "65", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "66", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "67", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "68", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "69", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "70", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "71", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "72", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "73", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "74", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "75", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "76", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "77", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "78", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "79", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "80", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "81", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "82", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "83", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "84", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "85", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "86", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "87", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "88", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "89", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "90", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "91", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "92", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "93", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "94", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "95", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "96", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "97", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "98", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "99", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "100", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "101", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "102", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "103", "ReferenceId": "32704382", "FullCitation": "Shan L, et al. Cell Discov (2020) pmid: 32704382", "Include": "true"}, {"number": "104", "ReferenceId": "23103869", "FullCitation": "Biankin AV, et al. Nature (2012) pmid: 23103869", "Include": "true"}, {"number": "105", "ReferenceId": "23260327", "FullCitation": "Foo WC, et al. Hum. Pathol. (2013) pmid: 23260327", "Include": "true"}, {"number": "106", "ReferenceId": "21984975", "FullCitation": "Ying H, et al. Cancer Discov (2011) pmid: 21984975", "Include": "true"}, {"number": "107", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "108", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "109", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "110", "ReferenceId": "23582881", "FullCitation": "Templeton AJ, et al. Eur. Urol. (2013) pmid: 23582881", "Include": "true"}, {"number": "111", "ReferenceId": "34246347", "FullCitation": "Sweeney C, et al. Lancet (2021) pmid: 34246347", "Include": "true"}, {"number": "112", "ReferenceId": "30037818", "FullCitation": "de Bono JS, et al. Clin. Cancer Res. (2019) pmid: 30037818", "Include": "true"}, {"number": "113", "ReferenceId": "27872130", "FullCitation": "Saura C, et al. Cancer Discov (2017) pmid: 27872130", "Include": "true"}, {"number": "114", "ReferenceId": "30327302", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302", "Include": "true"}, {"number": "115", "ReferenceId": "27091708", "FullCitation": "Andr\u00e9 F, et al. J. Clin. Oncol. (2016) pmid: 27091708", "Include": "true"}, {"number": "116", "ReferenceId": "31841354", "FullCitation": "Schmid P, et al. J. Clin. Oncol. (2019) pmid: 31841354", "Include": "true"}, {"number": "117", "ReferenceId": "30302599", "FullCitation": "Weldon Gilcrease G, et al. Invest New Drugs (2019) pmid: 30302599", "Include": "true"}, {"number": "118", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "119", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "120", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "121", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "122", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "123", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "124", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "125", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "126", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "127", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "128", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "129", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "130", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "131", "ReferenceId": "17150185", "FullCitation": "Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185", "Include": "true"}, {"number": "132", "ReferenceId": "8955068", "FullCitation": "Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068", "Include": "true"}, {"number": "133", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "134", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "135", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "136", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "137", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "138", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "139", "ReferenceId": "27147599", "FullCitation": "Kim E, et al. Cancer Discov (2016) pmid: 27147599", "Include": "true"}, {"number": "140", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "141", "ReferenceId": "21371307", "FullCitation": "Naguib A, et al. J Mol Signal (2011) pmid: 21371307", "Include": "true"}, {"number": "142", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "143", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "144", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "145", "ReferenceId": "19490892", "FullCitation": "Scholl C, et al. Cell (2009) pmid: 19490892", "Include": "true"}, {"number": "146", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "147", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "148", "ReferenceId": "2029511", "FullCitation": "Valencia A, et al. Biochemistry (1991) pmid: 2029511", "Include": "true"}, {"number": "149", "ReferenceId": "26854029", "FullCitation": "White Y, et al. Nat Commun (2016) pmid: 26854029", "Include": "true"}, {"number": "150", "ReferenceId": "8058307", "FullCitation": "Wiest JS, et al. Oncogene (1994) pmid: 8058307", "Include": "true"}, {"number": "151", "ReferenceId": "31289513", "FullCitation": "Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513", "Include": "true"}, {"number": "152", "ReferenceId": "24642870", "FullCitation": "Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870", "Include": "true"}, {"number": "153", "ReferenceId": "34117033", "FullCitation": "Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033", "Include": "true"}, {"number": "154", "ReferenceId": "17520196", "FullCitation": "Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196", "Include": "true"}, {"number": "155", "ReferenceId": "23565280", "FullCitation": "Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280", "Include": "true"}, {"number": "156", "ReferenceId": "8342602", "FullCitation": "Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602", "Include": "true"}, {"number": "157", "ReferenceId": "16549325", "FullCitation": "Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325", "Include": "true"}, {"number": "158", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "159", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "160", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "161", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "162", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "163", "ReferenceId": "21594619", "FullCitation": "Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619", "Include": "true"}, {"number": "164", "ReferenceId": "15483017", "FullCitation": "Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017", "Include": "true"}, {"number": "165", "ReferenceId": "16009947", "FullCitation": "Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947", "Include": "true"}, {"number": "166", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "167", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "168", "ReferenceId": "25897431", "FullCitation": "Garrido_Laguna I, et al. Oncoscience (2015) pmid: 25897431", "Include": "true"}, {"number": "169", "ReferenceId": "27975152", "FullCitation": "Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152", "Include": "true"}, {"number": "170", "ReferenceId": "23583440", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440", "Include": "true"}, {"number": "171", "ReferenceId": "24915778", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778", "Include": "true"}, {"number": "172", "ReferenceId": "29756206", "FullCitation": "Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206", "Include": "true"}, {"number": "173", "ReferenceId": "26251290", "FullCitation": "Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290", "Include": "true"}, {"number": "174", "ReferenceId": "27978579", "FullCitation": "Chung V, et al. JAMA Oncol (2017) pmid: 27978579", "Include": "true"}, {"number": "175", "ReferenceId": "25500057", "FullCitation": "Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057", "Include": "true"}, {"number": "176", "ReferenceId": "30833748", "FullCitation": "Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748", "Include": "true"}, {"number": "177", "ReferenceId": "30833752", "FullCitation": "Bryant KL, et al. Nat. Med. (2019) pmid: 30833752", "Include": "true"}, {"number": "178", "ReferenceId": "27039845", "FullCitation": "Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845", "Include": "true"}, {"number": "179", "ReferenceId": "29799479", "FullCitation": "Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479", "Include": "true"}, {"number": "180", "ReferenceId": "33128873", "FullCitation": "Guo C, et al. Lancet Oncol (2020) pmid: 33128873", "Include": "true"}, {"number": "181", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "182", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "183", "ReferenceId": "30683722", "FullCitation": "Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722", "Include": "true"}, {"number": "184", "ReferenceId": "32816843", "FullCitation": "Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843", "Include": "true"}, {"number": "185", "ReferenceId": "11780067", "FullCitation": "Lemon B, et al. Nature () pmid: 11780067", "Include": "true"}, {"number": "186", "ReferenceId": "21248752", "FullCitation": "Varela I, et al. Nature (2011) pmid: 21248752", "Include": "true"}, {"number": "187", "ReferenceId": "24185509", "FullCitation": "Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509", "Include": "true"}, {"number": "188", "ReferenceId": "18339845", "FullCitation": "Xia W, et al. Cancer Res. (2008) pmid: 18339845", "Include": "true"}, {"number": "189", "ReferenceId": "28921948", "FullCitation": "Hopson S, et al. ACS Chem. Biol. (2017) pmid: 28921948", "Include": "true"}, {"number": "190", "ReferenceId": "28053089", "FullCitation": "Porter EG, et al. J. Biol. Chem. (2017) pmid: 28053089", "Include": "true"}, {"number": "191", "ReferenceId": "26117423", "FullCitation": "Niimi A, et al. Mutat. Res. (2015) pmid: 26117423", "Include": "true"}, {"number": "192", "ReferenceId": "24613357", "FullCitation": "Brownlee PM, et al. Cell Rep (2014) pmid: 24613357", "Include": "true"}, {"number": "193", "ReferenceId": "25066234", "FullCitation": "Kakarougkas A, et al. Mol. Cell (2014) pmid: 25066234", "Include": "true"}, {"number": "194", "ReferenceId": "28082722", "FullCitation": "Gao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28082722", "Include": "true"}, {"number": "195", "ReferenceId": "25636086", "FullCitation": "Fujimoto A, et al. Nat Commun (2015) pmid: 25636086", "Include": "true"}, {"number": "196", "ReferenceId": "25536104", "FullCitation": "Churi CR, et al. PLoS ONE (2014) pmid: 25536104", "Include": "true"}, {"number": "197", "ReferenceId": "24867389", "FullCitation": "Simbolo M, et al. Oncotarget (2014) pmid: 24867389", "Include": "true"}, {"number": "198", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "199", "ReferenceId": "28988769", "FullCitation": "Robertson AG, et al. Cell (2017) pmid: 28988769", "Include": "true"}, {"number": "200", "ReferenceId": "28583311", "FullCitation": "Pietzak EJ, et al. Eur. Urol. (2017) pmid: 28583311", "Include": "true"}, {"number": "201", "ReferenceId": "32405805", "FullCitation": "Williams EA, et al. Acta Neuropathol. (2020) pmid: 32405805", "Include": "true"}, {"number": "202", "ReferenceId": "24974848", "FullCitation": "Petrini I, et al. Nat. Genet. (2014) pmid: 24974848", "Include": "true"}, {"number": "203", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "204", "ReferenceId": "24053427", "FullCitation": "da Costa WH, et al. BJU Int. (2014) pmid: 24053427", "Include": "true"}, {"number": "205", "ReferenceId": "22949125", "FullCitation": "Paw\u0142owski R, et al. Int. J. Cancer (2013) pmid: 22949125", "Include": "true"}, {"number": "206", "ReferenceId": "23036577", "FullCitation": "Hakimi AA, et al. Eur. Urol. (2013) pmid: 23036577", "Include": "true"}, {"number": "207", "ReferenceId": "23229642", "FullCitation": "Numata M, et al. Int. J. Oncol. (2013) pmid: 23229642", "Include": "true"}, {"number": "208", "ReferenceId": "23620406", "FullCitation": "Hakimi AA, et al. Clin. Cancer Res. (2013) pmid: 23620406", "Include": "true"}, {"number": "209", "ReferenceId": "22683710", "FullCitation": "Pe\u00f1a_Llopis S, et al. Nat. Genet. (2012) pmid: 22683710", "Include": "true"}, {"number": "210", "ReferenceId": "23333114", "FullCitation": "Kapur P, et al. Lancet Oncol. (2013) pmid: 23333114", "Include": "true"}, {"number": "211", "ReferenceId": "31486842", "FullCitation": "Braun DA, et al. JAMA Oncol (2019) pmid: 31486842", "Include": "true"}, {"number": "212", "ReferenceId": "32472114", "FullCitation": "Braun DA, et al. Nat Med (2020) pmid: 32472114", "Include": "true"}, {"number": "213", "ReferenceId": "29301960", "FullCitation": "Miao D, et al. Science (2018) pmid: 29301960", "Include": "true"}, {"number": "214", "ReferenceId": "32321774", "FullCitation": "Abou Alaiwi S, et al. Cancer Immunol Res (2020) pmid: 32321774", "Include": "true"}, {"number": "215", "ReferenceId": "32820162", "FullCitation": "Hakimi AA, et al. Nat Commun (2020) pmid: 32820162", "Include": "true"}, {"number": "216", "ReferenceId": "30150660", "FullCitation": "Miao D, et al. Nat. Genet. (2018) pmid: 30150660", "Include": "true"}, {"number": "217", "ReferenceId": "33850862", "FullCitation": "Yang Q, et al. Ann Transl Med (2021) pmid: 33850862", "Include": "true"}, {"number": "218", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "219", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "220", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "221", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "222", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "223", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "224", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "225", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "226", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "227", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "228", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "229", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "230", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "231", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "232", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "233", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "234", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "235", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "236", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "237", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "238", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "239", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "240", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "241", "ReferenceId": "22200773", "FullCitation": "Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773", "Include": "true"}, {"number": "242", "ReferenceId": "21507354", "FullCitation": "Prog Mol Biol Transl Sci (2011) pmid: 21507354", "Include": "true"}, {"number": "243", "ReferenceId": "21887466", "FullCitation": "Yang J, et al. Mol Med Rep () pmid: 21887466", "Include": "true"}, {"number": "244", "ReferenceId": "16870044", "FullCitation": "Vallb\u00f6hmer D, et al. Clin Lung Cancer (2006) pmid: 16870044", "Include": "true"}, {"number": "245", "ReferenceId": "21351083", "FullCitation": "Daskalos A, et al. Cancer (2011) pmid: 21351083", "Include": "true"}, {"number": "246", "ReferenceId": "17890317", "FullCitation": "Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317", "Include": "true"}, {"number": "247", "ReferenceId": "22011581", "FullCitation": "Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581", "Include": "true"}, {"number": "248", "ReferenceId": "23031157", "FullCitation": "Kim MS, et al. APMIS (2013) pmid: 23031157", "Include": "true"}, {"number": "249", "ReferenceId": "15861382", "FullCitation": "Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382", "Include": "true"}, {"number": "250", "ReferenceId": "25383530", "FullCitation": "Guo X, et al. Nature (2015) pmid: 25383530", "Include": "true"}, {"number": "251", "ReferenceId": "30705090", "FullCitation": "Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090", "Include": "true"}, {"number": "252", "ReferenceId": "29414941", "FullCitation": "Zhang ZM, et al. Nature (2018) pmid: 29414941", "Include": "true"}, {"number": "253", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "254", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "255", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "256", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "257", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "258", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "259", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "260", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "261", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "262", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "263", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "264", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "265", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "266", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "267", "ReferenceId": "29367431", "FullCitation": "Hu ZI, et al. Clin. Cancer Res. (2018) pmid: 29367431", "Include": "true"}, {"number": "268", "ReferenceId": "29056344", "FullCitation": "Campbell BB, et al. Cell (2017) pmid: 29056344", "Include": "true"}, {"number": "269", "ReferenceId": "29329208", "FullCitation": "Pihlak R, et al. Cancers (Basel) (2018) pmid: 29329208", "Include": "true"}, {"number": "270", "ReferenceId": "29523759", "FullCitation": "Salem ME, et al. Mol. Cancer Res. (2018) pmid: 29523759", "Include": "true"}, {"number": "271", "ReferenceId": "23029359", "FullCitation": "Laghi L, et al. PLoS ONE (2012) pmid: 23029359", "Include": "true"}, {"number": "272", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "273", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "274", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "275", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "276", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "277", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "278", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "279", "ReferenceId": "21566061", "FullCitation": "Ha K, et al. Mol. Cancer Ther. (2011) pmid: 21566061", "Include": "true"}, {"number": "280", "ReferenceId": "19034564", "FullCitation": "Liang Y, et al. World J Surg (2009) pmid: 19034564", "Include": "true"}, {"number": "281", "ReferenceId": "18519640", "FullCitation": "Mordes DA, et al. Genes Dev. (2008) pmid: 18519640", "Include": "true"}, {"number": "282", "ReferenceId": "12124347", "FullCitation": "Vassileva V, et al. Cancer Res. (2002) pmid: 12124347", "Include": "true"}, {"number": "283", "ReferenceId": "17384679", "FullCitation": "Miquel C, et al. Oncogene (2007) pmid: 17384679", "Include": "true"}, {"number": "284", "ReferenceId": "19570909", "FullCitation": "Jardim MJ, et al. Mol. Biol. Cell (2009) pmid: 19570909", "Include": "true"}, {"number": "285", "ReferenceId": "32456796", "FullCitation": "Zhou Y, et al. Biochem Biophys Res Commun (2020) pmid: 32456796", "Include": "true"}, {"number": "286", "ReferenceId": "21730979", "FullCitation": "Peasland A, et al. Br. J. Cancer (2011) pmid: 21730979", "Include": "true"}, {"number": "287", "ReferenceId": "16912188", "FullCitation": "McCabe N, et al. Cancer Res. (2006) pmid: 16912188", "Include": "true"}, {"number": "288", "ReferenceId": "1937255", "FullCitation": "Harefuah (1991) pmid: 1937255", "Include": "true"}, {"number": "289", "ReferenceId": "21258400", "FullCitation": "Sangster_Guity N, et al. Oncogene (2011) pmid: 21258400", "Include": "true"}, {"number": "290", "ReferenceId": "25025963", "FullCitation": "Del Conte G, et al. Br. J. Cancer (2014) pmid: 25025963", "Include": "true"}, {"number": "291", "ReferenceId": "30051098", "FullCitation": "Shroff RT, et al. JCO Precis Oncol (2018) pmid: 30051098", "Include": "true"}, {"number": "292", "ReferenceId": "34025781", "FullCitation": "Chi J, et al. Therap Adv Gastroenterol (2021) pmid: 34025781", "Include": "true"}, {"number": "293", "ReferenceId": "30110579", "FullCitation": "Litton JK, et al. N. Engl. J. Med. (2018) pmid: 30110579", "Include": "true"}, {"number": "294", "ReferenceId": "30124753", "FullCitation": "Ettl J, et al. Ann. Oncol. (2018) pmid: 30124753", "Include": "true"}, {"number": "295", "ReferenceId": "28242752", "FullCitation": "de Bono J, et al. Cancer Discov (2017) pmid: 28242752", "Include": "true"}, {"number": "296", "ReferenceId": "30099369", "FullCitation": "Lu E, et al. J Natl Compr Canc Netw (2018) pmid: 30099369", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_03_17 00:05:22", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "740x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": {"Amendmend": {"ModifiedDts": "2022_03_17 00:05:22", "IsSigned": "true", "Comment": "This Amended Report has been issued to reflect a change in Tumor Type from \"Unknown primary adenocarcinoma\" to \"Pancreas ductal adenocarcinoma\"; as a result, the therapy olaparib has been moved from \"Therapies with Clinical Relevance (In Other Tumor Type)\" to \"Therapies with Clinical Relevance (In Patient s Tumor Type)\" in association with the BRCA1 V11fs*12 alteration, and both olaparib and rucaparib are now listed as NCCN Category 2A. In addition, the Report Highlights table has been updated to account for the updated Tumor Type. Please reach out to Client Services with any questions or concerns. Contact us by phone at 1_888_988_3639 or by email at client.servicesfoundationmedicine.com. Original Report Date: 08_Mar_2022", "Type": "Amended"}}}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "PANCREAS", "disease_ontology": "Pancreas ductal adenocarcinoma", "flowcell_analysis": "2000020617", "gender": "female", "pathology_diagnosis": "Adenocarcinoma", "percent_tumor_nuclei": "20", "pipeline_version": "v3.10.1", "purity_assessment": "12.2", "specimen": "ORD_1311284_01*US1261351.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1311284_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Peritoneum", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "750.35", "name": "SQ_US1261351.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Qualified"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0798", "cds_effect": "3049_1G>A", "depth": "426", "equivocal": "false", "functional_effect": "splice", "gene": "PBRM1", "percent_reads": "7.98", "position": "chr3:52620705", "protein_effect": "splice site 3049_1G>A", "status": "likely", "strand": "_", "transcript": "NM_018313", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.0789", "cds_effect": "35G>A", "depth": "583", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "7.89", "position": "chr12:25398284", "protein_effect": "G12D", "status": "known", "strand": "_", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.4887", "cds_effect": "320G>A", "depth": "751", "equivocal": "false", "functional_effect": "missense", "gene": "MAP3K13", "percent_reads": "48.87", "position": "chr3:185146689", "protein_effect": "G107E", "status": "unknown", "strand": "+", "transcript": "NM_004721", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.4474", "cds_effect": "2169C>A", "depth": "818", "equivocal": "false", "functional_effect": "nonsense", "gene": "ERCC4", "percent_reads": "44.74", "position": "chr16:14041622", "protein_effect": "C723*", "status": "unknown", "strand": "+", "transcript": "NM_005236", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.3975", "cds_effect": "6792C>G", "depth": "639", "equivocal": "false", "functional_effect": "missense", "gene": "POLE", "percent_reads": "39.75", "position": "chr12:133201352", "protein_effect": "H2264Q", "status": "unknown", "strand": "_", "transcript": "NM_006231", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.4822", "cds_effect": "6893G>A", "depth": "842", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH2", "percent_reads": "48.22", "position": "chr1:120458452", "protein_effect": "R2298Q", "status": "unknown", "strand": "_", "transcript": "NM_024408", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.4618", "cds_effect": "11G>A", "depth": "511", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "46.18", "position": "chr20:57428331", "protein_effect": "R4H", "status": "unknown", "strand": "+", "transcript": "NM_080425", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.016", "cds_effect": "2711C>T", "depth": "561", "equivocal": "false", "functional_effect": "missense", "gene": "DNMT3A", "percent_reads": "1.6", "position": "chr2:25457176", "protein_effect": "P904L", "status": "known", "strand": "_", "transcript": "NM_022552", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.4634", "cds_effect": "130G>A", "depth": "546", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR3", "percent_reads": "46.34", "position": "chr4:1801001", "protein_effect": "G44S", "status": "unknown", "strand": "+", "transcript": "NM_000142", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.2763", "cds_effect": "1299_1334del36", "depth": "561", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "GNAS", "percent_reads": "27.63", "position": "chr20:57429618", "protein_effect": "A436_P447del", "status": "unknown", "strand": "+", "transcript": "NM_080425", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.523", "cds_effect": "32delT", "depth": "608", "equivocal": "false", "functional_effect": "frameshift", "gene": "BRCA1", "percent_reads": "52.3", "position": "chr17:41276081", "protein_effect": "V11fs*12", "status": "likely", "strand": "_", "transcript": "NM_007294", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"allele_fraction": "0.0756", "cds_effect": "6316G>T", "depth": "622", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "7.56", "position": "chr19:15272123", "protein_effect": "D2106Y", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}]}, "copy_number_alterations": null, "rearrangements": {"rearrangement": [{"description": "ATR(NM_001184) duplication intron 35 _ intron 36", "equivocal": "false", "in_frame": "No", "other_gene": "ATR", "pos1": "chr3:142203939_142204256", "pos2": "chr3:142207838_142208242", "status": "likely", "supporting_read_pairs": "44", "targeted_gene": "ATR", "type": "duplication", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}, {"description": "PTEN(NM_000314) duplication intron 3 _ intron 4", "equivocal": "false", "in_frame": "No", "other_gene": "PTEN", "pos1": "chr10:89690626_89690938", "pos2": "chr10:89686225_89686528", "status": "likely", "supporting_read_pairs": "63", "targeted_gene": "PTEN", "type": "duplication", "dna_evidence": {"sample": "SQ_US1261351.01_1"}}]}, "biomarkers": {"microsatellite_instability": {"status": "unknown"}, "tumor_mutation_burden": {"score": "1.26", "status": "unknown", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}